Empagliflozin prevents doxorubicin-induced myocardial dysfunction

Table 2 Study endpoints at 6 weeks

	Controls	DOX group	DOX + EMPA group	DOX + FURO group
Weight, g	23.18 ± 1.8	21.45 ± 2.7	22.5 ± 2.1	21.8 ± 2.4
Glucose, mg/dl	200.6 ± 40	166.6 ± 72	205.5 ± 39	170.5 ± 50
Systolic pressure, mmHg	121 ± 15	102 ± 37	119 ± 20*	105 ± 33
Diastolic pressure, mmHg	76 ± 11	41 ± 10	65 ± 28*	60 ± 24*
LVEF, %	68.7 ± 5%	49.24 ± 8	61.30 ± 11*	55.79 ± 11
LVFS, %	39.4 ± 3%	24.70 ± 5	33.08 ± 8*	28.62 ± 8
LVEDd, mm	3.11 ± 0.1	3.98 ± 0.4	3.89 ± 0.3	3.80 ± 0.7
LVESd, mm	1.93 ± 0.5	2.98 ± 0.4	2.67 ± 0.5	2.73 ± 0.5
IVS, mm	0.81 ± 0.001	0.69 ± 0.004	0.77 ± 0.001*	0.77 ± 0.005*
PW, mm	0.78 ± 0.001	0.71 ± 0.005	0.76 ± 0.013	0.76 ± 0.014
Longitudinal strain (LS),%	− 24.1 ± 4%	− 13.93 ± 5	− 17.52 ± 3*	− 16.1 ± 3.5
Circumferential strain (CS), %	− 29.9 ± 8%	− 15.91 ± 6	− 25.75 ± 6*	− 15.8 ± 3.3
Radial strain (RS), %	46.0 ± 7%	26.7 ± 13	24.0 ± 5	26.1 ± 4
E/A	1.6 ± 0.1	1.7 ± 0.2	1.6 ± 0.2	1.5 ± 0.1
E/Eʹ	41.1 ± 2.2	77.3 ± 3.5	61.1 ± 5.7*	59.4 ± 4*

Values are mean ± SD, or n (%)
LVEF left ventricular ejection fraction, LVFS left ventricular fractional shortening, IVS interventricular septum, PW posterior wall
*p < 0.05 compared to DOX

ISSN: 1475-2840